Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report details a specific share repurchase transaction executed on August 12, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 900,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,272.5 pence per share; lowest price paid was 1,239.5 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 502,996,816 shares in Treasury.
- Treasury Percentage: Represents 8.98% of total issued share capital and 9.87% of total voting rights.
- Shares in Issue: 5,095,582,623 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's issued share capital through the cancellation of 900,000 repurchased shares. Consequently, the total number of shares in issue decreased to 5,095,582,623. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total issued share capital of 5,095,582,623 for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the Treasury share count of 502,996,816 and its impact on voting rights (9.87%).
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.